Fresenius Medical Care climbs to four-month high, Goldman optimism supports shares
23.06.2026 - 09:09:32 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 09:02.
Fresenius Medical Care (DE0005785802) draws renewed attention on Xetra after a positive analyst note from Goldman Sachs and a move to the highest level since February. According to a dpa-AFX broker report carried by MarketScreener, the shares touched 41.58 euros on Monday, while Goldman’s Richard Felton signaled optimism for the upcoming quarter.
What Goldman Sachs expects
The dpa-AFX broker commentary quotes Goldman analyst Richard Felton as expecting Fresenius Medical Care to deliver another solid improvement in operating profit in the next quarterly report in early August.MarketScreener summary of the dpa-AFX broker note The report highlights that same-market treatment volume growth in the United States likely remained sluggish, underscoring that volume trends remain a key variable for the investment case.
Analysts repeatedly describe rising U.S. treatment volumes as crucial for a sustained re-rating of Fresenius Medical Care shares, given the company’s large dialysis presence in the world’s most profitable healthcare market.Finanzen.net analyst overview for Fresenius Medical Care Goldman’s constructive stance therefore carries weight in a sector where large peers such as DaVita in the US also trade closely in line with perceived volume momentum.
Shares at highest level since February
According to the broker commentary, Fresenius Medical Care shares climbed on Monday to 41.58 euros, the highest level since February, before the Xetra close.MarketScreener summary of the dpa-AFX broker note This places the stock clearly above its autumn 2022 low around 26 euros that followed a long drawdown from a peak near 94 euros in February 2018.
The medium-term performance remains muted compared with some healthcare names in the DAX and Stoxx Europe 600 Health Care, but the recent recovery indicates that investors are again willing to price in gradual operational progress at the dialysis specialist.Finanzen100 price data for Fresenius Medical Care That said, analysts still stress the importance of stable reimbursement frameworks and labor cost management in the group’s key markets.
Background and price data on Fresenius Medical Care
All recent news, key figures and historical quotes for the Fresenius Medical Care shares are collected in the dedicated topic section and on the company’s investor-relations pages.
How Fresenius Medical Care earns its money
Fresenius Medical Care generates the bulk of its revenue with chronic kidney failure treatments and services, above all regular hemodialysis in outpatient centers and hospitals worldwide.Company information on Fresenius Medical Care In addition to the treatment side, the group produces and sells dialysis machines, dialyzers and related disposables that are used both in its own centers and by external providers.
Where the shares trade now
The Fresenius Medical Care shares (DE0005785802) last traded on Xetra at 41.58 euros on 2026-06-22, 17:35, according to exchange data, putting the company’s equity value in the mid single-digit billion-euro range.
Fresenius Medical Care at a glance
- Company: Fresenius Medical Care AG
- ISIN: DE0005785802
- WKN: 578580
- Ticker: FME
- Trading venue: Xetra
- Price (as of 2026-06-22, 17:35): 41.58 EUR
- Market cap: around 9.9 billion EUR (as of 2026-06-22)
- Sector / industry: Health Care - Healthcare Providers & Services
- Index membership: DAX
- Next earnings date: 2026-08-01 (company guidance: early August quarterly release)
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any financial instrument. Figures and dates are based on publicly available sources believed to be reliable but are not guaranteed for accuracy or completeness.
